Abstract
Abstract Introduction Adults seeking non-pharmacological treatment for insomnia often present for care already taking prescription medication for sleep. Understanding how such patients differ from those who do not use medication could be useful for guiding treatment. This study examined associations between sleep medication use and measures of self-report sleep characteristics at baseline in an RCT of cognitive behavioral therapy for insomnia (CBTI). Methods We examined baseline data from 237 middle-to-older-aged adults with insomnia disorder (175 women, M age = 63.17) enrolled in the ongoing RCT on Effectiveness of Stepped-Care Sleep Therapy (RESTING). Participants were dichotomized by whether they reported taking at least one prescription medication for sleep. Sleep measures included the Insomnia Severity Index (ISI), PROMIS Sleep-Related Impairment short form, Epworth Sleepiness Scale (ESS), Cognitive Presleep Arousal Scale, Dysfunctional Attitudes and Beliefs About Sleep Scale, and two weeks of sleep diaries yielding average nightly sleep onset latency, wake time after sleep onset, total sleep time, and sleep quality ratings. MANOVA compared medication users and non-users across sleep measures. Results Seventy-seven (32.5%) participants reported taking at least one prescription medication for sleep at baseline. MANOVA results indicated that sleep measures collectively differed by medication use, F(9, 226) = 3.74, p < .001; Wilk’s Λ = .87, partial η-sqd = .13. Bonferroni-adjusted follow-up comparisons (p < .005) found that only ESS significantly differed between medication users and non-users, F(1, 234) = 15.17, p < .001; partial η-sqd = .06. Medication users had lower sleepiness scores (M = 5.86, SD = 4.68) than non-users (M = 8.46, SD = 4.84). The association between medication use and less daytime sleepiness was maintained after adjusting for ISI. Conclusion Sleep medication use displayed little association with sleep measures in adults about to undergo CBTI, excepting endorsement of less daytime sleepiness by medication users. While more research is needed to understand the implications of sleep medication use for adults engaging in CBTI, these initial findings suggest that CBTI therapists should be thoughtful about sleepiness in non-medication users, and the potential emergence of sleepiness among patients who engage in sleep medication taper while in treatment. Support (If Any) 1R01AG057500
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.